CELEX: C2007/056/31
Language: en
Date: 2007-03-10 00:00:00
Title: Case C-515/06 P: Appeal brought on 19 December 2006 by European Association of Euro Pharmaceutical Companies (EAEPC) against the judgment of the Court of First Instance (Fourth Chamber, Extended Composition) delivered on 27 September 2006 in Case T-168/01: GlaxoSmithKline Services Unlimited v Commission of the European Communities

10.3.2007   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 56/18
            
         Appeal brought on 19 December 2006 by European Association of Euro Pharmaceutical Companies (EAEPC) against the judgment of the Court of First Instance (Fourth Chamber, Extended Composition) delivered on 27 September 2006 in Case T-168/01: GlaxoSmithKline Services Unlimited v Commission of the European Communities
   (Case C-515/06 P)
   (2007/C 56/31)
   Language of the case: English
   Parties
   
      Appellant: European Association of Euro Pharmaceutical Companies (EAEPC) (represented by: M. Hartmann-Rüppel and W. Rehmann, Rechtsanwälte)
   
      Other parties to the proceedings: Commission of the European Communities, Bundesverband der Arzneimittel-Importeure eV, Spain Pharma, SA, Asociación de exportadores españoles de productos farmacéuticos (Aseprofar), GlaxoSmithKline Services Unlimited, anciennement Glaxo Wellcome plc
   Form of order sought
   The applicant claims that the Court should:
   
               —
            
            
               set aside the judgment of the Court of First Instance of 27 September 2006, case no. T-168/01, to the extent the Court of First Instance annulled the Commission decision 2001/70/E (1) of 8 May 2001.
            
         
               —
            
            
               to award the costs of the proceedings before the Court of Justice and the Court of First Instance.
            
         Pleas in law and main arguments
   The Appellant claims the following infringements of Community law by the appealed judgment:
   
               (a)
            
            
               Misapplication of Art. 81(3) EC-the Court of First Instance disregarded the role and function of Art. 81(3) when alleging the assessment undertaken by the Commission was insufficient.
            
         
               (b)
            
            
               Misapplication of Article 81(3) EC by misjudging the burden of rendering evidence and proof
            
         
               (c)
            
            
               Misapplication of Article 81(3) EC in consequence of misinterpretation or non-consideration of evidence on file, which proves that the applicant (GSK) did not plead on the requirements of Article 81(3) EC sufficiently and by offering sustainable evidence.
            
         
      (1)  OJ L 302, p. 1.